Mechanistically, we demonstrated that AXL, an emerging target for cancer therapy, was a novel protein substrate of GALNT2 and GALNT2 regulated AXL degradation primarily through the proteasome‐dependent pathway. This evidence concerns the gene GALNT2 and cancer.